Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 763

Sort by

Sort Order Select

Journal Articles

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Joshua D. Brody, Judit Meszaros Jørgensen, Dr, David Belada, Régis Costello, Marek Trněný, Umberto Vitolo, David John Lewis, Yasmin H. Karimi, Anna Sureda, Marc Andre, Björn E. Wahlin, Pieternella J. Lugtenburg, Tony Jiang, Kubra Karagoz, Andrew J Steele, Aqeel Abbas, Liwei Wang, Malene Risum, Raul Cordoba

Blood blood.2024026830.

https://doi.org/10.1182/blood.2024026830

Published: 2025

Includes: Supplemental data

Journal Articles

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Blood blood.2022019306.

https://doi.org/10.1182/blood.2022019306

Published: 2024

Includes: Supplemental data

Journal Articles

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Blood blood.2024025738.

https://doi.org/10.1182/blood.2024025738

Published: 2024

Includes: Supplemental data

Journal Articles

Immunotherapy with pVAX14 Nucleic Acid in Combination with All-Trans Retinoic Acid (ATRA) in an Acute Promyelocytic Leukemia (APL) Mouse Model Activates Cytotoxic T-Cells and Enhances Immune Responses: A Strategy for Turning “Cold” Tumors “Hot”

Rose Ann Padua, Satyananda Patel, James Smith, Dr Omidvar, Nilgun Tekin, Fabien Guidez, Mathieu Chiquet, Niclas Setterblad, Ken I Mills, Marika PLA, Patricia Krief, Thierry Huet, Christine Chomienne, Pierre Fenaux

Blood (2024) 144 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2024-201513

Published: 2024

Journal Articles

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Frank W.G. Leebeek, Karina Meijer, Michiel Coppens, Peter Kampmann, Dr. Klamroth, Paul van der Valk, Paul E. Monahan, Karen Pinachyan, Sandra LeQuellec, Wolfgang Miesbach

Blood (2024) 144 (Supplement 1): 3578.

https://doi.org/10.1182/blood-2024-198379

Published: 2024

Journal Articles

Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Beta Thalassemia Major: Experience from Resource Constrained Centers

Khalil Ur Rahman, Parvez Ahmed, Shahzad Sarwar, Shahzad Nasir, Umar Zahur, Muhammad Nadeem, Saba Tazeen, Summaira Naseeb, Uzair Ahmed, Dr Asghar Ali, Hina Peter, Muhammad Afzal, Qamar Un Nisa Chaudhry, Syed Karman Mahmood, Sumyyia Abbasi, Mehroz Fatima

Blood (2024) 144 (Supplement 1): 7296.

https://doi.org/10.1182/blood-2024-210225

Published: 2024

Journal Articles

Impact of Variable Recombinant Factor VIII Binding on Platelet Functions

Anja Strebel, Fabrizio Pennacchio, Sebastian Lickert, Dr. Klamroth, Viola Vogel

Blood (2024) 144 (Supplement 1): 5462.

https://doi.org/10.1182/blood-2024-193865

Published: 2024

Journal Articles

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

Inga M. Schimansky, Andreas Tiede, Christiane Dobbelstein, Dr. Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul N. Knöbl, Johannes Oldenburg, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Moehnle, Katharina Holstein, Wolfgang A. Miesbach

Blood (2024) 144 (Supplement 1): 555.

https://doi.org/10.1182/blood-2024-205490

Published: 2024

Journal Articles

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Lucia Masarova, Helen T Chifotides, Dr.

Blood blood.2023022415.

https://doi.org/10.1182/blood.2023022415

Published: 2024

Includes: Supplemental data

Journal Articles

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Dr. Peters, Peter Bader, Ulrike Pötschger, M. Akif Yesilipek, Herbert Pichler, Franco Locatelli, Raquel Staciuk, Adriana Balduzzi, Gergely Krivan, Marianne Ifversen, Cristina Díaz De Heredia, Marc Bierings, Jacek Wachowiak, Jean-Hugues Dalle

Blood (2023) 142 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2023-185870

Published: 2023

Journal Articles

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Prof. Uttam Kumar Nath, Karthik Kumar, Adamya Gupta, Reshma Benson, DR Arjun Kachhwaha

Blood (2023) 142 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2023-188377

Published: 2023

Journal Articles

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Blood (2023) 142 (Supplement 1): 473.

https://doi.org/10.1182/blood-2023-172704

Published: 2023

Journal Articles

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Krzysztof Kalwak, Peter Bader, Jean-Hugues Dalle, Petr Sedlacek, Jochen Buechner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Diaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Ulrike Poetschger, Dr. Peters, Franco Locatelli

Blood (2023) 142 (Supplement 1): 232.

https://doi.org/10.1182/blood-2023-180728

Published: 2023

Journal Articles

To Study Outcomes in Young CML Treated with TKI. a Registry Data from Hematological Cancer Consortium (HCC) of India

Blood (2023) 142 (Supplement 1): 4542.

https://doi.org/10.1182/blood-2023-181369

Published: 2023

Journal Articles

Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India

Kishore Kumar, Chezhian Subash, Durai Prabhu, Manikandan R, Senthooran Dr

Blood (2023) 142 (Supplement 1): 6178.

https://doi.org/10.1182/blood-2023-172649

Published: 2023

Journal Articles

High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

Blood (2022) 140 (Supplement 1): 4303–4304.

https://doi.org/10.1182/blood-2022-170346

Published: 2022

Journal Articles

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Dr. Maryam Alomran, Cameron Wellard, Pin-Yen Chen, Elizabeth M. Moore, Wee Joo Chng

Blood (2022) 140 (Supplement 1): 10075–10076.

https://doi.org/10.1182/blood-2022-164613

Published: 2022

Journal Articles

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Susan Klaeger, Eugen Tausch, Binyamin A. Knisbacher, Annie Apffel, Karl R Clauser, Corinne Williams, Clary Clish, Laura Z. Rassenti, Thomas J. Kipps, Kirsten Fischer, Michael Hallek, Michael A Gillette, Donna S. Neuberg, Gad Getz, DR Mani, Stephan Stilgenbauer, Catherine J. Wu, Steven A Carr

Blood (2022) 140 (Supplement 1): 9838–9839.

https://doi.org/10.1182/blood-2022-167843

Published: 2022

Journal Articles

Identification of Risk Factors for and Development of a Predictive Model for Immunotherapy-Associated Venous Thromboembolism (VTE) in Patients with Non-Small Cell Lung Cancer

Kristen M. Sanfilippo, Suhong Luo, Gary H. Lyman, David C. Calverley, Dr. Nicole M.M. Kuderer

Blood (2022) 140 (Supplement 1): 2803–2804.

https://doi.org/10.1182/blood-2022-165748

Published: 2022

Journal Articles

Toxicity Reporting Is Inconsistent and Incomplete, and Subjective Minimizing Language Is Common in Acute Leukemia Clinical Trials: A Systematic Review of Randomized Controlled Trials Presented at ASH between 2017-2021

Benjamin Chin-Yee, Turab Mohammed, Clarissa Skorupski, Bishal Gyawali, Gary H. Lyman, Lisa K. Hicks, Dr. Nicole M.M. Kuderer

Blood (2022) 140 (Supplement 1): 317–318.

https://doi.org/10.1182/blood-2022-157860

Published: 2022

NARROW

Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation

Inflammatory Waldenström Macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort

Immunotherapy with pVAX14 Nucleic Acid in Combination with All-Trans Retinoic Acid (ATRA) in an Acute Promyelocytic Leukemia (APL) Mouse Model Activates Cytotoxic T-Cells and Enhances Immune Responses: A Strategy for Turning “Cold” Tumors “Hot”

Stable Factor IX Expression and Sustained Reductions in Factor IX Use 8 Years after Gene Therapy with CSL220 (Formerly AMT-060) in Adults with Hemophilia B

Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Patients with Beta Thalassemia Major: Experience from Resource Constrained Centers

Impact of Variable Recombinant Factor VIII Binding on Platelet Functions

Sustained Improvement of Survival in Patients Receiving Emicizumab Prophylaxis Instead of Immunosuppression during Early Management of Acquired Hemophilia a (AHA)

How I individualize selection of JAK inhibitors for patients with myelofibrosis

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Measurable Residual Disease Results & Survival with Augmented Early Intensification Therapy in Intermediate-Risk & High-Risk Group Pediatric Acute Lymphoblastic Leukemia Patients Treated with ALL IC-BFM 2009 Protocol: A Single-Center Study from India

Treosulfan Compared to Busulfan in Allogeneic Haematopoietic Stem Cell Transplantation for Myelofibrosis: A Registry-Based Study from the Chronic Malignancies Working Party of the EBMT

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

To Study Outcomes in Young CML Treated with TKI. a Registry Data from Hematological Cancer Consortium (HCC) of India

Hodgkin Lymphoma - Mitigating Toxicity While Preserving Cure - Eight Year Data from MIOT International, Chennai, India

High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients

How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Identification of Risk Factors for and Development of a Predictive Model for Immunotherapy-Associated Venous Thromboembolism (VTE) in Patients with Non-Small Cell Lung Cancer

Toxicity Reporting Is Inconsistent and Incomplete, and Subjective Minimizing Language Is Common in Acute Leukemia Clinical Trials: A Systematic Review of Randomized Controlled Trials Presented at ASH between 2017-2021

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only